Premium
Erenumab: a monoclonal antibody for migraine prophylaxis
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1750
Subject(s) - medicine , calcitonin gene related peptide , migraine , monoclonal antibody , calcitonin , adverse effect , monoclonal , pharmacology , antibody , receptor , immunology , neuropeptide
Erenumab (Aimovig) is a monoclonal antibody targeting the calcitonin gene‐related peptide (CGRP) receptor that has been licensed for the prophylaxis of migraine in adults who have at least four migraine days per month. This article discusses its efficacy, adverse effects and place in therapy.